Inclisiran 与心血管事件:III 期试验的患者水平汇总分析
该研究对 ORION-9、-10、-11 三项 III 期试验进行患者水平汇总分析,纳入杂合子家族性高胆固醇血症、动脉粥样硬化性心血管疾病或 ASCVD 风险等效且已接受最大耐受他汀治疗的患者,随机接受 inclisiran 284 mg 或安慰剂。第 90 天时 LDL-C 安慰剂校正降幅为 50.6%(绝对降幅 1.37 mmol/L,P<0.0001)。18 个月内 inclisiran 显著降低复合 MACE(OR 0.74,95%CI 0.58-0.94),但未显著降低致死与非致死性心肌梗死或卒中。
要点
- inclisiran 每半年皮下注射一次,第 90 天 LDL-C 降幅达 50.6%。
- 18 个月时复合 MACE 风险显著降低(OR 0.74,95%CI 0.58-0.94)。
- 致死与非致死性心梗及卒中风险未显著降低,结论待更长 CVOT 确认。
核心结论
- 该分析提示 inclisiran 降低 LDL-C 可能带来 MACE 方面的潜在获益,但需更大规模、更长期的心血管结局试验确认。
研究设计与样本
- 对 ORION-9、-10、-11 三项 III 期试验进行患者水平汇总分析,纳入杂合子家族性高胆固醇血症、ASCVD 或 ASCVD 风险等效且已接受最大耐受他汀治疗的患者。
- 患者按 1:1 随机接受 inclisiran 284 mg 或安慰剂,在第 1 天、第 90 天及之后每 6 个月给药,持续 18 个月。
主要发现
- 基线平均 LDL-C 为 2.88 mmol/L,第 90 天 inclisiran 组安慰剂校正的 LDL-C 降幅为 50.6%,绝对降幅 1.37 mmol/L(均 P < 0.0001)。
- 在 3655 例患者中,18 个月内 303 例(8.3%)发生 MACE,包括 74 例(2.0%)致死与非致死性心肌梗死和 28 例(0.8%)致死与非致死性卒中。
- inclisiran 显著降低复合 MACE(OR 0.74,95%CI 0.58-0.94)。
- inclisiran 未显著降低致死与非致死性心肌梗死(OR 0.80,95%CI 0.50-1.27)或致死与非致死性卒中(OR 0.86,95%CI 0.41-1.81)。
临床怎么用
- 对于已接受最大耐受他汀治疗的高危 ASCVD 患者,inclisiran 可作为进一步降低 LDL-C 的选项之一。
- 现有数据支持 inclisiran 可能降低复合 MACE,但心梗和卒中方面的获益尚未确立,需等待心血管结局试验结果。
局限性
- MACE 为预设探索性终点,基于安全性评估中的标准化 MedDRA 检索篮,事件未经裁定。
- 致死与非致死性心梗和卒中分析非预设,且随访仅 18 个月。
- 研究结论尚需更大规模、更长随访的心血管结局试验确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inclisiran, an siRNA administered twice-yearly, significantly reduced LDL cholesterol (LDL-C) in Phase III trials. Whether lowering LDL-C with inclisiran translates into a lower risk of cardiovascular (CV) events is not yet established. METHODS AND RESULTS: Patient-level, pooled analysis of ORION-9, -10 and -11, included patients with heterozygous familial hypercholesterolaemia, atherosclerotic CV disease (ASCVD), or ASCVD risk equivalent on maximally tolerated statin-therapy, randomized 1:1 to receive 284 mg inclisiran or placebo on Days 1, 90, and 6-monthly thereafter for 18 months. Prespecified exploratory endpoint of major cardiovascular events (MACEs) included non-adjudicated CV death, cardiac arrest, non-fatal myocardial infarction (MI), and fatal and non-fatal stroke, evaluated as part of safety assessments using a standard Medical Dictionary for Regulatory Activities basket. Although not prespecified, total fatal and non-fatal MI, and stroke were also evaluated. Mean LDL-C at baseline was 2.88 mmol/L. At Day 90, the placebo-corrected percentage reduction in LDL-C with inclisiran was 50.6%, corresponding to an absolute reduction of 1.37 mmol/L (both P < 0.0001). Among 3655 patients over 18 months, 303 (8.3%) experienced MACE, including 74 (2.0%) fatal and non-fatal MIs, and 28 (0.8%) fatal and non-fatal strokes. Inclisiran significantly reduced composite MACE [OR (95% CI): 0.74 (0.58-0.94)], but not fatal and non-fatal MIs [OR (95% CI): 0.80 (0.50-1.27)] or fatal and non-fatal stroke [OR (95% CI): 0.86 (0.41-1.81)]. CONCLUSION: This analysis offers early insights into the potential CV benefits of lowering LDL-C with inclisiran and suggests potential benefits for MACE reduction. These findings await confirmation in the larger CV outcomes trials of longer duration.
引用
- Ray KK, Raal FJ, Kallend DG, et al. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur Heart J. 2023. PMID: 36331326. doi:10.1093/eurheartj/ehac594
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。